Brenig Therapeutics – a neurology-focused drug development company utilizing an AI/ML-based discovery platform – announced the closing of a $65 million Series A funding.
The funding was led by New Enterprise Associates (NEA) with support from an additional US-based healthcare investor and existing investors: OrbiMed, Torrey Pines Investments and BioGeneration Ventures. In connection with the financing, Ed Mathers, Partner at NEA, will join the Board of Directors.
Brenig plans to use the funding to advance BT-267 through healthy volunteer studies and into proof-of-concept studies in idiopathic Parkinson’s disease patients. And the company will explore advancing additional best-in-class approaches for Parkinson’s disease.
KEY QUOTES:
“With the financing, we advance our goal of addressing the needs of Parkinson’s disease patients with our differentiated drugs.”
- Iain Dukes MA DPhil, Chairman of Brenig
“The Brenig team has made remarkable progress since inception. We believe their approach could lead to best-in-class therapeutics for the treatment of Parkinson’s disease. NEA is thrilled to partner with Brenig through its next phase of growth.”
- Ed Mathers, partner at NEA
